India to Serbia: Aminophylline Export Trade Route

To import finished pharmaceutical formulations containing Aminophylline into Serbia, the following regulatory steps are required:

2. Approval Timelines: The evaluation and approval process typically takes between 6 to 12 months, depending on the completeness of the submitted documentation and the complexity of the product.

3. Registration Fees: Fees are determined based on the type of application and the specific product. Applicants should consult the National DRA's official fee schedule for precise amounts.

Indian manufacturers exporting Aminophylline formulations to Serbia must adhere to the following quality and GMP standards:

3. Approved Facilities: As of March 2026, specific details regarding Indian facilities approved by the National DRA for Aminophylline formulations are not publicly disclosed. Manufacturers should maintain up-to-date GMP certifications and be prepared for potential inspections.

4. Regulatory Actions: There have been no publicly reported regulatory actions by the National DRA against Indian pharmaceutical companies concerning Aminophylline formulations in the past 18 months.

Between September 2024 and March 2026, several regulatory developments have impacted the importation of pharmaceutical products into Serbia:

These developments underscore the importance for Indian exporters to stay informed about regulatory changes and maintain rigorous compliance to ensure uninterrupted access to the Serbian pharmaceutical market.

TARIFF_NOTES: Pharmaceutical products, including aminophylline formulations, are typically exempt from import duties in Serbia, facilitating access to essential medicines.

The Serbian market for aminophylline formulations is influenced by the prevalence of respiratory conditions such as chronic obstructive pulmonary disease (COPD) and asthma. While specific market size data for Serbia is limited, the global aminophylline market is projected to grow at a compound annual growth rate (CAGR) of 2.3% from 2024 to 2030, driven by increasing respiratory disorders and a preference for cost-effective treatments. In Serbia, the demand for aminophylline formulations is supported by an aging population and universal health coverage, which ensures access to essential medications. The country imports aminophylline formulations to meet domestic demand, with India being a notable supplier. Domestic manufacturing capabilities for aminophylline formulations in Serbia are limited, necessitating reliance on imports to fulfill market needs.

Serbia applies a 0% MFN import duty rate on pharmaceutical products classified under HS code 30049099, which includes aminophylline formulations. This duty-free status aligns with Serbia's commitment to ensuring the availability of essential medicines. Additionally, Serbia's value-added tax (VAT) system may apply to pharmaceutical imports; however, specific VAT rates and any exemptions for pharmaceuticals should be verified with Serbian customs authorities. As of March 2026, there is no free trade agreement (FTA) between India and Serbia that specifically affects pharmaceutical tariffs. Furthermore, there are no anti-dumping duties imposed on aminophylline formulations imported into Serbia.

India is a significant supplier of aminophylline formulations to Serbia, accounting for 11.1% of India's total aminophylline formulation exports, valued at $0.7 million USD. The primary Indian exporter is BRAWN LABORATORIES LIMITED, with ZEFARM D.O.O. being the main Serbian importer. Other major countries supplying aminophylline formulations to Serbia include European Union member states and China. India's pricing for aminophylline formulations is competitive compared to European manufacturers, offering cost-effective options without compromising quality. This competitive pricing, combined with India's established pharmaceutical manufacturing capabilities, positions Indian exporters favorably in the Serbian market.

India is a leading global supplier of generic pharmaceuticals, accounting for approximately 20% of the world's generic medicine supply by volume as of 2024. The country's pharmaceutical industry is valued at over $50 billion, with exports exceeding $25 billion in the 2022-2023 financial year.

The nation boasts a robust manufacturing infrastructure, with over 650 U.S. FDA-approved facilities and more than 2,000 WHO-GMP-certified plants as of 2024. This extensive network enables large-scale production of finished dosage forms, including tablets, capsules, syrups, and injections. The cost-effectiveness of Indian manufacturing is attributed to economies of scale, a skilled workforce, and favorable regulatory policies. These factors collectively position India as a preferred source for Aminophylline formulations globally.

India's Aminophylline formulation exports are competitively priced compared to those from China and the European Union. The country's cost advantages stem from efficient production processes and lower labor costs. In terms of quality, Indian pharmaceutical manufacturers adhere to stringent international standards, with numerous facilities approved by regulatory bodies such as the U.S. FDA and the European Medicines Agency (EMA). This compliance ensures high-quality products that meet global standards. Serbia's regulatory authorities recognize and accept Indian pharmaceutical products, facilitating smoother import processes. Indian manufacturers have a strong track record of supply reliability, with consistent delivery schedules and adherence to contractual obligations.

The India-Serbia Aminophylline formulation supply chain is robust, supported by India's substantial manufacturing capacity for finished dosage forms. The country's pharmaceutical industry has demonstrated resilience, with no significant supply disruptions reported in recent years. Indian manufacturers maintain high standards of regulatory compliance, with a notable decrease in U.S. FDA Official Action Indicated (OAI) instances by 50% over the past decade. Leading Indian pharmaceutical companies have announced expansion plans to further increase production capacities, ensuring the ability to meet growing international demand.

• Implement a Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply chain disruptions and ensure a consistent supply of Aminophylline formulations.

• Negotiate Favorable Minimum Order Quantities (MOQs): Indian suppliers typically offer flexible MOQs; however, establishing clear agreements can optimize inventory management and cost efficiency.

• Establish Clear Payment Terms: Common payment terms in India-Serbia pharmaceutical trade include letters of credit (LC) and advance payments. Clearly define terms to ensure mutual understanding and smooth transactions.

• Conduct Comprehensive Supplier Qualification: Evaluate potential suppliers based on regulatory compliance, manufacturing capabilities, quality assurance processes, and past performance to ensure alignment with your quality and reliability standards.

• Monitor Regulatory Compliance: Regularly review the regulatory status of selected suppliers to ensure ongoing compliance with international standards, thereby maintaining product quality and market access.

1. Verify Manufacturer's Registration with CDSCO: Confirm that the Indian manufacturer is registered with the Central Drugs Standard Control Organization (CDSCO), India's national regulatory authority overseeing pharmaceutical products.

2. Assess Validity of GMP Certification: Ensure the manufacturer holds a valid Good Manufacturing Practice (GMP) certificate, indicating adherence to quality standards in production processes.

3. Review Drug Master File (DMF): Obtain and evaluate the DMF, which provides detailed information on the manufacturing process, controls, and specifications of the Aminophylline formulation.

4. Confirm Product Registration in Serbia: Verify that the Aminophylline formulation is registered with the Medicines and Medical Devices Agency of Serbia (ALIMS), ensuring compliance with local regulatory requirements.

5. Evaluate Quality Management Systems: Assess the manufacturer's quality management systems to ensure they meet international standards, such as ISO 9001:2015, for consistent product quality.

6. Check for Additional Certifications: Look for certifications like WHO-GMP or EU-GMP, which demonstrate compliance with international quality standards.

7. Review Export History: Examine the manufacturer's export history to ensure experience in supplying to international markets, particularly within the European Union.

8. Conduct Risk Assessment: Perform a risk assessment of the supplier, considering factors such as financial stability, supply chain reliability, and past regulatory compliance issues.

1. Certificate of Analysis (CoA): Provides detailed results of laboratory testing for a specific batch, confirming the product meets predefined specifications.

2. Certificate of Origin (CoO): Certifies the country where the product was manufactured, essential for customs and regulatory purposes.

3. GMP Certificate: Issued by the relevant regulatory authority, confirming the manufacturing facility complies with Good Manufacturing Practices.

4. Stability Data: Includes studies conducted under International Council for Harmonisation (ICH) guidelines to demonstrate the product's shelf life and stability under various conditions.

5. Batch Manufacturing Records: Detailed documentation of the production process for each batch, ensuring traceability and consistency.

6. Drug Master File (DMF): Comprehensive document detailing the manufacturing process, controls, and specifications of the drug product.

7. Free Sale Certificate: Issued by CDSCO, indicating the product is approved for sale in India and is freely marketed without restrictions.

8. Insurance Certificates: Proof of liability insurance coverage, ensuring protection against potential claims related to product quality or safety.

1. Recent Regulatory Actions: Be cautious of manufacturers with recent warning letters or sanctions from regulatory bodies such as the U.S. FDA or WHO, indicating compliance issues.

2. Suspension of GMP Certification: A suspended or revoked GMP certificate suggests significant quality management failures.

3. Unusually Low Pricing: Prices significantly below market rates may indicate compromised quality or substandard manufacturing practices.

4. Lack of Stability Data: Inability to provide comprehensive stability data raises concerns about the product's shelf life and efficacy.

5. Limited Export Experience: Suppliers without a track record of exporting to regulated markets may lack the necessary quality assurance systems.

6. Resistance to Audits: Hesitation or refusal to allow facility audits suggests potential compliance or quality issues.

1. Pre-Audit Desktop Review: Conduct a thorough review of the supplier's documentation, including quality manuals, SOPs, and previous audit reports.

3. Post-Audit Corrective Actions: Require the supplier to address any identified deficiencies with a corrective and preventive action (CAPA) plan, including timelines for implementation.

4. Annual Re-Qualification: Schedule annual audits to ensure ongoing compliance and continuous improvement.

5. Remote Monitoring Options: Utilize virtual audits and regular communication to monitor compliance between on-site visits.

6. Cost Estimates and Timelines: Budget approximately $5,000 to $10,000 USD for an on-site audit, including travel expenses, with the process typically taking 3 to 5 days.

By adhering to this structured approach, Serbian companies can effectively qualify Indian suppliers of Aminophylline formulations, ensuring product quality and regulatory compliance.